Share Price and Basic Stock Data
Last Updated: January 8, 2026, 7:55 pm
| PEG Ratio | 0.66 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Coral Laboratories Ltd, operating in the pharmaceuticals sector, reported a current share price of ₹460 and a market capitalization of ₹164 Cr. The company has experienced fluctuating revenue trends, with sales for the trailing twelve months (TTM) standing at ₹89 Cr. This reflects a notable increase from ₹78 Cr reported in the previous fiscal year ending March 2023. The quarterly sales figures indicate variability, with a significant dip to ₹11.44 Cr in March 2023, followed by a recovery in the subsequent quarters, culminating in ₹23.15 Cr in September 2023. This pattern suggests a potential rebound in demand, though the company must maintain this momentum to ensure sustainable growth. The overall sales trajectory over the years shows a gradual increase, with ₹115 Cr projected for March 2025, compared to ₹76 Cr in March 2022, highlighting a robust growth strategy that the company is pursuing.
Profitability and Efficiency Metrics
Coral Laboratories Ltd reported an operating profit margin (OPM) of 25.96%, indicating a strong operational efficiency relative to the industry average. The company recorded a net profit of ₹17 Cr for the latest period, translating to a net profit margin of 21.00%, which is commendable against typical sector benchmarks. The return on equity (ROE) stood at 13.1%, while the return on capital employed (ROCE) was 17.4%, reflecting effective capital utilization. The interest coverage ratio (ICR) reported at an extraordinary 362.17x underscores the company’s ability to meet its interest obligations comfortably, given its minimal borrowings of ₹1 Cr. However, the cash conversion cycle (CCC) at 129 days raises some concerns, as it indicates a longer duration to convert investments into cash, potentially affecting liquidity. Overall, the profitability metrics demonstrate a sound financial position, but improvements in operational cycles are necessary for enhanced cash flow.
Balance Sheet Strength and Financial Ratios
The balance sheet of Coral Laboratories Ltd reflects a strong financial position with total assets recorded at ₹229 Cr as of March 2025. The company maintained reserves of ₹210 Cr, showcasing a solid capital base. With borrowings at only ₹1 Cr, the debt-to-equity ratio is exceptionally low at 0.01, highlighting minimal financial leverage and a conservative approach to financing. The current ratio stands at 7.07, indicating ample liquidity to cover short-term liabilities. Additionally, the price-to-book value (P/BV) ratio is 1.25x, suggesting that the stock is reasonably valued compared to its book value. The company’s asset turnover ratio at 0.52% signifies efficient use of assets in generating revenue. However, the historical trend shows fluctuations in profitability, which could indicate potential volatility in earnings stability. Overall, Coral Laboratories presents a robust balance sheet, but continuous monitoring of financial ratios is essential to maintain its strong standing.
Shareholding Pattern and Investor Confidence
Coral Laboratories Ltd has a stable shareholding pattern, with promoters holding a significant 71.51% stake, which reflects strong insider confidence in the company’s future. The foreign institutional investors (FIIs) have a negligible presence at 0.00%, indicating limited external interest, while the public holds 28.49% of the shares. Over the past few quarters, the number of shareholders has increased from 4,110 in December 2022 to 4,286 by September 2025, suggesting growing investor interest. This increase in shareholders could be a sign of enhanced market confidence in the company’s growth trajectory. However, the absence of institutional investments may limit the stock’s liquidity and could deter larger investments. The consistent promoter holding signifies a commitment to long-term growth, but the company needs to attract institutional investors to bolster its market presence and stability.
Outlook, Risks, and Final Insight
Coral Laboratories Ltd is positioned for growth, with a clear upward trend in sales and profitability metrics. However, the company faces certain risks, including the longer cash conversion cycle which could impact liquidity and operational efficiency. Additionally, reliance on a concentrated promoter holding might lead to governance risks if not balanced with broader institutional participation. On the upside, the solid financial ratios, low debt levels, and strong operational efficiency present significant strengths that could drive future growth. The company must continue to improve its operational cycles while exploring avenues to attract institutional investors to enhance its market appeal. In a scenario where operational efficiencies are optimized, and investor confidence strengthens, Coral Laboratories could unlock substantial growth potential, positioning itself favorably in the competitive pharmaceuticals sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 208/84.3 | 28.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,404 Cr. | 404 | 479/192 | 91.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.0 Cr. | 39.6 | 41.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,548.25 Cr | 1,144.26 | 53.56 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 25.70 | 24.73 | 11.44 | 13.55 | 23.15 | 18.08 | 28.89 | 31.66 | 32.23 | 22.99 | 28.13 | 18.82 | 19.03 |
| Expenses | 21.39 | 23.88 | 13.52 | 11.81 | 17.00 | 15.98 | 22.64 | 20.92 | 25.72 | 16.67 | 25.44 | 16.64 | 14.09 |
| Operating Profit | 4.31 | 0.85 | -2.08 | 1.74 | 6.15 | 2.10 | 6.25 | 10.74 | 6.51 | 6.32 | 2.69 | 2.18 | 4.94 |
| OPM % | 16.77% | 3.44% | -18.18% | 12.84% | 26.57% | 11.62% | 21.63% | 33.92% | 20.20% | 27.49% | 9.56% | 11.58% | 25.96% |
| Other Income | 2.21 | 1.54 | 1.16 | 1.29 | 1.81 | 1.37 | 2.00 | 1.56 | 2.54 | 2.52 | 1.71 | 2.05 | 3.03 |
| Interest | 0.11 | 0.11 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.01 | 0.02 | 0.04 | 0.06 | 0.10 |
| Depreciation | 0.50 | 0.50 | 0.68 | 0.55 | 0.44 | 0.49 | 0.50 | 0.49 | 0.51 | 0.50 | 0.51 | 0.45 | 0.45 |
| Profit before tax | 5.91 | 1.78 | -1.62 | 2.48 | 7.52 | 2.98 | 7.75 | 11.78 | 8.53 | 8.32 | 3.85 | 3.72 | 7.42 |
| Tax % | 17.26% | 51.69% | -45.06% | 26.21% | 20.21% | 27.52% | 25.16% | 25.21% | 25.21% | 26.08% | 26.49% | 31.18% | 21.56% |
| Net Profit | 4.89 | 0.86 | -0.89 | 1.84 | 6.00 | 2.16 | 5.79 | 8.80 | 6.38 | 6.14 | 2.83 | 2.56 | 5.82 |
| EPS in Rs | 13.69 | 2.41 | -2.49 | 5.15 | 16.79 | 6.05 | 16.21 | 24.63 | 17.86 | 17.19 | 7.92 | 7.17 | 16.29 |
Last Updated: December 27, 2025, 11:02 am
Below is a detailed analysis of the quarterly data for Coral Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 19.03 Cr.. The value appears strong and on an upward trend. It has increased from 18.82 Cr. (Jun 2025) to 19.03 Cr., marking an increase of 0.21 Cr..
- For Expenses, as of Sep 2025, the value is 14.09 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.64 Cr. (Jun 2025) to 14.09 Cr., marking a decrease of 2.55 Cr..
- For Operating Profit, as of Sep 2025, the value is 4.94 Cr.. The value appears strong and on an upward trend. It has increased from 2.18 Cr. (Jun 2025) to 4.94 Cr., marking an increase of 2.76 Cr..
- For OPM %, as of Sep 2025, the value is 25.96%. The value appears strong and on an upward trend. It has increased from 11.58% (Jun 2025) to 25.96%, marking an increase of 14.38%.
- For Other Income, as of Sep 2025, the value is 3.03 Cr.. The value appears strong and on an upward trend. It has increased from 2.05 Cr. (Jun 2025) to 3.03 Cr., marking an increase of 0.98 Cr..
- For Interest, as of Sep 2025, the value is 0.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.06 Cr. (Jun 2025) to 0.10 Cr., marking an increase of 0.04 Cr..
- For Depreciation, as of Sep 2025, the value is 0.45 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.45 Cr..
- For Profit before tax, as of Sep 2025, the value is 7.42 Cr.. The value appears strong and on an upward trend. It has increased from 3.72 Cr. (Jun 2025) to 7.42 Cr., marking an increase of 3.70 Cr..
- For Tax %, as of Sep 2025, the value is 21.56%. The value appears to be improving (decreasing) as expected. It has decreased from 31.18% (Jun 2025) to 21.56%, marking a decrease of 9.62%.
- For Net Profit, as of Sep 2025, the value is 5.82 Cr.. The value appears strong and on an upward trend. It has increased from 2.56 Cr. (Jun 2025) to 5.82 Cr., marking an increase of 3.26 Cr..
- For EPS in Rs, as of Sep 2025, the value is 16.29. The value appears strong and on an upward trend. It has increased from 7.17 (Jun 2025) to 16.29, marking an increase of 9.12.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:55 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 59 | 77 | 95 | 92 | 91 | 71 | 97 | 76 | 78 | 84 | 115 | 89 |
| Expenses | 41 | 47 | 60 | 72 | 77 | 79 | 65 | 81 | 67 | 74 | 67 | 89 | 73 |
| Operating Profit | 10 | 12 | 16 | 23 | 15 | 12 | 5 | 16 | 8 | 4 | 16 | 26 | 16 |
| OPM % | 20% | 21% | 21% | 24% | 17% | 14% | 8% | 16% | 11% | 5% | 19% | 23% | 18% |
| Other Income | 1 | 3 | 3 | 3 | 4 | 5 | 6 | 4 | 6 | 7 | 6 | 8 | 9 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 10 | 12 | 17 | 25 | 18 | 16 | 9 | 18 | 12 | 8 | 21 | 32 | 23 |
| Tax % | 21% | 22% | 29% | 34% | 31% | 34% | 22% | 23% | 24% | 22% | 24% | 26% | |
| Net Profit | 8 | 10 | 12 | 16 | 12 | 10 | 7 | 14 | 9 | 6 | 16 | 24 | 17 |
| EPS in Rs | 22.03 | 26.79 | 34.71 | 45.63 | 34.85 | 28.61 | 19.96 | 37.93 | 25.33 | 18.05 | 44.20 | 67.63 | 48.57 |
| Dividend Payout % | 9% | 9% | 9% | 11% | 6% | 7% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 25.00% | 20.00% | 33.33% | -25.00% | -16.67% | -30.00% | 100.00% | -35.71% | -33.33% | 166.67% | 50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -5.00% | 13.33% | -58.33% | 8.33% | -13.33% | 130.00% | -135.71% | 2.38% | 200.00% | -116.67% |
Coral Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 10% |
| 3 Years: | 15% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 28% |
| 3 Years: | 44% |
| TTM: | -19% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 9% |
| 3 Years: | 21% |
| 1 Year: | -48% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 9% |
| 3 Years: | 9% |
| Last Year: | 13% |
Last Updated: September 5, 2025, 3:01 pm
Balance Sheet
Last Updated: January 7, 2026, 5:16 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves | 47 | 56 | 67 | 106 | 113 | 110 | 112 | 133 | 152 | 151 | 174 | 198 | 210 |
| Borrowings | 0 | 1 | 0 | 2 | 2 | 1 | 6 | 6 | 6 | -0 | -0 | 4 | 1 |
| Other Liabilities | 10 | 12 | 19 | 20 | 22 | 21 | 23 | 25 | 28 | 20 | 28 | 25 | 19 |
| Total Liabilities | 60 | 72 | 89 | 131 | 140 | 136 | 144 | 168 | 190 | 174 | 206 | 229 | 233 |
| Fixed Assets | 20 | 19 | 18 | 18 | 22 | 23 | 23 | 21 | 24 | 25 | 24 | 23 | 24 |
| CWIP | -0 | -0 | -0 | 0 | -0 | -0 | -0 | 0 | 2 | -0 | -0 | 2 | 14 |
| Investments | 1 | 1 | 5 | 39 | 45 | 28 | 25 | 33 | 46 | 41 | 50 | 52 | 57 |
| Other Assets | 40 | 52 | 67 | 74 | 73 | 84 | 97 | 112 | 118 | 108 | 132 | 152 | 138 |
| Total Assets | 60 | 72 | 89 | 131 | 140 | 136 | 144 | 168 | 190 | 174 | 206 | 229 | 233 |
Below is a detailed analysis of the balance sheet data for Coral Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00 Cr..
- For Reserves, as of Sep 2025, the value is 210.00 Cr.. The value appears strong and on an upward trend. It has increased from 198.00 Cr. (Mar 2025) to 210.00 Cr., marking an increase of 12.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 4.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 3.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 19.00 Cr.. The value appears to be improving (decreasing). It has decreased from 25.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 6.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 233.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 229.00 Cr. (Mar 2025) to 233.00 Cr., marking an increase of 4.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 24.00 Cr.. The value appears strong and on an upward trend. It has increased from 23.00 Cr. (Mar 2025) to 24.00 Cr., marking an increase of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 14.00 Cr., marking an increase of 12.00 Cr..
- For Investments, as of Sep 2025, the value is 57.00 Cr.. The value appears strong and on an upward trend. It has increased from 52.00 Cr. (Mar 2025) to 57.00 Cr., marking an increase of 5.00 Cr..
- For Other Assets, as of Sep 2025, the value is 138.00 Cr.. The value appears to be declining and may need further review. It has decreased from 152.00 Cr. (Mar 2025) to 138.00 Cr., marking a decrease of 14.00 Cr..
- For Total Assets, as of Sep 2025, the value is 233.00 Cr.. The value appears strong and on an upward trend. It has increased from 229.00 Cr. (Mar 2025) to 233.00 Cr., marking an increase of 4.00 Cr..
Notably, the Reserves (210.00 Cr.) exceed the Borrowings (1.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 10.00 | 11.00 | 16.00 | 21.00 | 13.00 | 11.00 | -1.00 | 10.00 | 2.00 | 4.00 | 16.00 | 22.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 109 | 152 | 132 | 117 | 125 | 122 | 178 | 148 | 184 | 109 | 123 | 107 |
| Inventory Days | 97 | 110 | 110 | 155 | 120 | 116 | 176 | 158 | 169 | 100 | 149 | 68 |
| Days Payable | 61 | 66 | 80 | 75 | 87 | 91 | 129 | 108 | 81 | 34 | 130 | 46 |
| Cash Conversion Cycle | 145 | 196 | 162 | 197 | 157 | 146 | 225 | 198 | 272 | 176 | 142 | 129 |
| Working Capital Days | 158 | 194 | 179 | 164 | 161 | 171 | 241 | 178 | 222 | 221 | 183 | 140 |
| ROCE % | 21% | 22% | 27% | 28% | 16% | 13% | 8% | 13% | 7% | 5% | 13% | 17% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 67.61 | 44.19 | 18.04 | 25.32 | 37.94 |
| Diluted EPS (Rs.) | 67.61 | 44.19 | 18.04 | 25.32 | 37.94 |
| Cash EPS (Rs.) | 73.24 | 49.72 | 24.14 | 30.89 | 43.49 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 563.19 | 496.83 | 433.29 | 436.81 | 382.48 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 563.19 | 496.83 | 433.29 | 436.81 | 382.48 |
| Dividend / Share (Rs.) | 1.50 | 2.00 | 0.00 | 0.00 | 0.00 |
| Revenue From Operations / Share (Rs.) | 321.91 | 234.17 | 218.66 | 211.64 | 270.30 |
| PBDIT / Share (Rs.) | 98.94 | 64.02 | 29.97 | 36.47 | 54.91 |
| PBIT / Share (Rs.) | 93.31 | 58.49 | 23.87 | 30.89 | 49.37 |
| PBT / Share (Rs.) | 90.89 | 58.03 | 23.02 | 33.19 | 49.25 |
| Net Profit / Share (Rs.) | 67.61 | 44.19 | 18.04 | 25.32 | 37.94 |
| PBDIT Margin (%) | 30.73 | 27.33 | 13.70 | 17.23 | 20.31 |
| PBIT Margin (%) | 28.98 | 24.97 | 10.91 | 14.59 | 18.26 |
| PBT Margin (%) | 28.23 | 24.78 | 10.53 | 15.67 | 18.21 |
| Net Profit Margin (%) | 21.00 | 18.87 | 8.25 | 11.96 | 14.03 |
| Return on Networth / Equity (%) | 12.00 | 8.89 | 4.16 | 5.79 | 9.91 |
| Return on Capital Employeed (%) | 16.30 | 11.55 | 5.24 | 6.71 | 12.61 |
| Return On Assets (%) | 10.52 | 7.67 | 3.69 | 4.76 | 8.09 |
| Total Debt / Equity (X) | 0.01 | 0.00 | 0.00 | 0.03 | 0.04 |
| Asset Turnover Ratio (%) | 0.52 | 0.44 | 0.42 | 0.42 | 0.61 |
| Current Ratio (X) | 7.07 | 6.18 | 10.42 | 5.13 | 3.99 |
| Quick Ratio (X) | 6.68 | 5.57 | 9.36 | 4.41 | 3.21 |
| Inventory Turnover Ratio (X) | 9.19 | 2.87 | 2.68 | 1.92 | 2.39 |
| Dividend Payout Ratio (NP) (%) | 2.95 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 2.73 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 97.05 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 97.27 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 362.17 | 114356.50 | 31.63 | 92.33 | 461.63 |
| Interest Coverage Ratio (Post Tax) (X) | 256.38 | 79763.50 | 19.93 | 58.31 | 319.93 |
| Enterprise Value (Cr.) | 174.27 | 71.40 | 41.37 | 59.77 | 86.55 |
| EV / Net Operating Revenue (X) | 1.52 | 0.85 | 0.52 | 0.79 | 0.89 |
| EV / EBITDA (X) | 4.93 | 3.12 | 3.86 | 4.59 | 4.41 |
| MarketCap / Net Operating Revenue (X) | 2.18 | 1.59 | 1.05 | 1.21 | 1.19 |
| Retention Ratios (%) | 97.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 1.25 | 0.74 | 0.52 | 0.58 | 0.84 |
| Price / Net Operating Revenue (X) | 2.18 | 1.59 | 1.05 | 1.21 | 1.19 |
| EarningsYield | 0.09 | 0.11 | 0.07 | 0.09 | 0.11 |
After reviewing the key financial ratios for Coral Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 24) to 67.61, marking an increase of 23.42.
- For Diluted EPS (Rs.), as of Mar 25, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 24) to 67.61, marking an increase of 23.42.
- For Cash EPS (Rs.), as of Mar 25, the value is 73.24. This value is within the healthy range. It has increased from 49.72 (Mar 24) to 73.24, marking an increase of 23.52.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 563.19. It has increased from 496.83 (Mar 24) to 563.19, marking an increase of 66.36.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 563.19. It has increased from 496.83 (Mar 24) to 563.19, marking an increase of 66.36.
- For Dividend / Share (Rs.), as of Mar 25, the value is 1.50. This value is within the healthy range. It has decreased from 2.00 (Mar 24) to 1.50, marking a decrease of 0.50.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 321.91. It has increased from 234.17 (Mar 24) to 321.91, marking an increase of 87.74.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 98.94. This value is within the healthy range. It has increased from 64.02 (Mar 24) to 98.94, marking an increase of 34.92.
- For PBIT / Share (Rs.), as of Mar 25, the value is 93.31. This value is within the healthy range. It has increased from 58.49 (Mar 24) to 93.31, marking an increase of 34.82.
- For PBT / Share (Rs.), as of Mar 25, the value is 90.89. This value is within the healthy range. It has increased from 58.03 (Mar 24) to 90.89, marking an increase of 32.86.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 67.61. This value is within the healthy range. It has increased from 44.19 (Mar 24) to 67.61, marking an increase of 23.42.
- For PBDIT Margin (%), as of Mar 25, the value is 30.73. This value is within the healthy range. It has increased from 27.33 (Mar 24) to 30.73, marking an increase of 3.40.
- For PBIT Margin (%), as of Mar 25, the value is 28.98. This value exceeds the healthy maximum of 20. It has increased from 24.97 (Mar 24) to 28.98, marking an increase of 4.01.
- For PBT Margin (%), as of Mar 25, the value is 28.23. This value is within the healthy range. It has increased from 24.78 (Mar 24) to 28.23, marking an increase of 3.45.
- For Net Profit Margin (%), as of Mar 25, the value is 21.00. This value exceeds the healthy maximum of 10. It has increased from 18.87 (Mar 24) to 21.00, marking an increase of 2.13.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.00. This value is below the healthy minimum of 15. It has increased from 8.89 (Mar 24) to 12.00, marking an increase of 3.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.30. This value is within the healthy range. It has increased from 11.55 (Mar 24) to 16.30, marking an increase of 4.75.
- For Return On Assets (%), as of Mar 25, the value is 10.52. This value is within the healthy range. It has increased from 7.67 (Mar 24) to 10.52, marking an increase of 2.85.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.52. It has increased from 0.44 (Mar 24) to 0.52, marking an increase of 0.08.
- For Current Ratio (X), as of Mar 25, the value is 7.07. This value exceeds the healthy maximum of 3. It has increased from 6.18 (Mar 24) to 7.07, marking an increase of 0.89.
- For Quick Ratio (X), as of Mar 25, the value is 6.68. This value exceeds the healthy maximum of 2. It has increased from 5.57 (Mar 24) to 6.68, marking an increase of 1.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.19. This value exceeds the healthy maximum of 8. It has increased from 2.87 (Mar 24) to 9.19, marking an increase of 6.32.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 2.95. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 24) to 2.95, marking an increase of 2.95.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 2.73. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 24) to 2.73, marking an increase of 2.73.
- For Earning Retention Ratio (%), as of Mar 25, the value is 97.05. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 97.05, marking an increase of 97.05.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 97.27. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 97.27, marking an increase of 97.27.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 362.17. This value is within the healthy range. It has decreased from 114,356.50 (Mar 24) to 362.17, marking a decrease of 113,994.33.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 256.38. This value is within the healthy range. It has decreased from 79,763.50 (Mar 24) to 256.38, marking a decrease of 79,507.12.
- For Enterprise Value (Cr.), as of Mar 25, the value is 174.27. It has increased from 71.40 (Mar 24) to 174.27, marking an increase of 102.87.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.52. This value is within the healthy range. It has increased from 0.85 (Mar 24) to 1.52, marking an increase of 0.67.
- For EV / EBITDA (X), as of Mar 25, the value is 4.93. This value is below the healthy minimum of 5. It has increased from 3.12 (Mar 24) to 4.93, marking an increase of 1.81.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.18. This value is within the healthy range. It has increased from 1.59 (Mar 24) to 2.18, marking an increase of 0.59.
- For Retention Ratios (%), as of Mar 25, the value is 97.04. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 24) to 97.04, marking an increase of 97.04.
- For Price / BV (X), as of Mar 25, the value is 1.25. This value is within the healthy range. It has increased from 0.74 (Mar 24) to 1.25, marking an increase of 0.51.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.18. This value is within the healthy range. It has increased from 1.59 (Mar 24) to 2.18, marking an increase of 0.59.
- For EarningsYield, as of Mar 25, the value is 0.09. This value is below the healthy minimum of 5. It has decreased from 0.11 (Mar 24) to 0.09, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Coral Laboratories Ltd:
- Net Profit Margin: 21%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.3% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 256.38
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 6.68
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 9.19 (Industry average Stock P/E: 53.56)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 21%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 3B, Patanwala Compound, Mumbai Maharashtra 400086 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajendrasinh Rana | Director |
| Mr. Girish M Dhameja | Whole Time Director |
| Mrs. Sushma Kadkade | Director & CFO |
| Ms. Pooja Hindia | Independent Director |
| Dr. Saurabh Shah | Independent Director |
| Mr. Malay Doshi | Independent Director |
FAQ
What is the intrinsic value of Coral Laboratories Ltd?
Coral Laboratories Ltd's intrinsic value (as of 08 January 2026) is ₹575.91 which is 26.85% higher the current market price of ₹454.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹162 Cr. market cap, FY2025-2026 high/low of ₹851/429, reserves of ₹210 Cr, and liabilities of ₹233 Cr.
What is the Market Cap of Coral Laboratories Ltd?
The Market Cap of Coral Laboratories Ltd is 162 Cr..
What is the current Stock Price of Coral Laboratories Ltd as on 08 January 2026?
The current stock price of Coral Laboratories Ltd as on 08 January 2026 is ₹454.
What is the High / Low of Coral Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Coral Laboratories Ltd stocks is ₹851/429.
What is the Stock P/E of Coral Laboratories Ltd?
The Stock P/E of Coral Laboratories Ltd is 9.19.
What is the Book Value of Coral Laboratories Ltd?
The Book Value of Coral Laboratories Ltd is 596.
What is the Dividend Yield of Coral Laboratories Ltd?
The Dividend Yield of Coral Laboratories Ltd is 0.33 %.
What is the ROCE of Coral Laboratories Ltd?
The ROCE of Coral Laboratories Ltd is 17.4 %.
What is the ROE of Coral Laboratories Ltd?
The ROE of Coral Laboratories Ltd is 13.1 %.
What is the Face Value of Coral Laboratories Ltd?
The Face Value of Coral Laboratories Ltd is 10.0.